Primary Endpoint and Analysis Model for Prevention Trials with Participants with Preclinical AD: Lessons Learned from the DIAN‐TU Platform Trial
Our experience from the DIAN-TU platform trial suggests that time-to-recurrent-event is a more effective endpoint for preclinical AD trials. Survival analysis provides more tangible and clinically relevant insights by translating treatment effects into reductions in hazard rates or extended survival times.
Authors
- Guoqiao Wang
- Yan Li
Institutions
- Washington University in St. Louis (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_099564
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00